SCHEMBL4726151

SCHEMBL4726151

COc1cc(N)c2nc(C3CCCC3)ccc2c1C1CCCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE3B Q13370 1/20 0.40
PDE3A Q14432 1/20 0.40
CDK4 P11802 2/20 0.36
CCND1 P24385 2/20 0.36
CDK1 P06493 1/20 0.36
CCNB1 P14635 1/20 0.36
CCNE1 P24864 1/20 0.36
CDK2 P24941 1/20 0.36
ADORA2A P29274 1/20 0.35
NSD2 O96028 1/20 0.35
CASP6 P55212 1/20 0.35
PDGFRB P09619 1/20 0.35
PDGFRA P16234 1/20 0.35
G6PD P11413 1/20 0.35
CNR2 P34972 6/20 0.34
CNR1 P21554 5/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 2/20 0.34
HPGD P15428 2/20 0.34
HSD17B10 Q99714 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4729342 0.99 PDE3B (0.39) PDE3BPDE3ACDK4CCND1CDK1
SCHEMBL5083088 0.86 TUBB4A (0.39) PDE3BPDE3ACDK1ADORA2ANSD2
SCHEMBL4727418 0.79 PDE3B (0.39) PDE3BPDE3ACNR2KDM4EALDH1A1
SCHEMBL4725352 0.79 NSD2 (0.59) CDK4CCND1CDK1CCNB1CCNE1
SCHEMBL4782008 0.78 PDE3B (0.38) PDE3BPDE3ACNR2KDM4EALDH1A1
SCHEMBL5086649 0.78 NSD2 (0.58) CDK4CCND1CDK1CCNB1CCNE1
SCHEMBL4725459 0.77 EHMT2 (0.35) PDE3BPDE3ACDK4CCND1CDK1
SCHEMBL5086202 0.76 EHMT2 (0.36) PDE3BPDE3AADORA2ACNR2CNR1
SCHEMBL4726521 0.74 MAOA (0.44) PDE3ANSD2CASP6KDM4EALDH1A1
SCHEMBL5084097 0.73 MAOA (0.43) PDE3ANSD2CASP6KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008021210-A2 METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS COMBINATORX, INCORPORATED (US) 2008-02-21 WO disclosed
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders CHDI, INCORPORATED 2008-02-21 US disclosed
US-6979740-B2 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (IN) 2005-12-27 US disclosed
EP-1606263-A1 RING-SUBSTITUTED 8-AMINOQUINOLINE DERIVATIVES AS ANTIMALARIAL AGENTS Council of Scientific and Industrial Research (IN) 2005-12-21 EP disclosed
WO-2004085402-A1 RING-SUBSTITUTED 8-AMINOQUNOLINE DERIVATES AS ANTIMALARIAL AGENTS COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) 2004-10-07 WO disclosed
US-20040192724-A1 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH DEPARTMENT OF PHARMACEUTICAL TECHNOLOGY (IN) 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192724-A1 Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents QDPR, SLC11A2, CYP2C8 PDE3B 155/4885PDE3A 331/4885CDK4 1907/4885
US-20080044390-A1 Methods and compositions for the treatment of neurodegenerative disorders HTT, SNCA, NLN PDE3B 1021/4885PDE3A 969/4885CDK4 3176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.